Ichnos Glenmark Innovation

News

AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody

AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Ichnos Glenmark Innovation

Editor's Picks